---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-041520"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2024-02-21T23:59:59+00:00"
generated_at: "2026-06-05T21:52:36.392558+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Catalyst announces VISION-DMD vamorolone study published in Neurology

## Summary
- Peer-reviewed journal Neurology published Santhera's VISION-DMD study on vamorolone (AGAMREE) for DMD.
- Study of 121 boys aged 4 to <7 years showed 6 mg/kg/d vamorolone maintained motor improvements to 48 weeks.
- Vamorolone reversed prednisone-induced bone morbidities including stunted growth and bone biomarker decline.
- Catalyst holds exclusive North American commercialization rights for AGAMREE, already approved in US.
- Results support long-term efficacy and safety profile of vamorolone for Duchenne muscular dystrophy.

## SEC filing metadata
- accession: 0001193125-24-041520
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2024-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312524041520/0001193125-24-041520-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312524041520/d706892d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-041520
- JSON: https://secwatch.observer/filing/0001193125-24-041520.json
- Plain text: https://secwatch.observer/filing/0001193125-24-041520.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.